title: Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects.
abstract: BACKGROUND
  Colorectal cancer is a devastating disease with a dismal prognosis which is heavily hampered by delayed diagnosis. Surgical resection, radiation therapy and chemotherapy are the curative options. Due to few therapeutic treatments available i.e., mono and combination therapy and development of resistance towards drug response, novel and efficacious therapy are urgently needed.
  
  
  OBJECTIVE
  In this study, we have studied the potential of histone deacetylase inhibitors in colorectal cancer.
  
  
  RESULTS
  Histone deacetylase inhibitors (HDACIs) are an emerging class of therapeutic agents having potential anticancer activity with minimal toxicity for different types of malignancies in preclinical studies. HDACIs have proven less effective in monotherapy thus the combination of HDACIs with other anticancer agents are being assessed for the treatment of colorectal cancer.
  
  
  CONCLUSIONS
  The molecular mechanism emphasizing the anticancer effect of HDACIs in colorectal cancer was illustrated and a recapitulation was carried out on the recent advances in the rationale behind combination therapies currently underway in clinical evaluations.
authors.affiliation: Medicinal Chemistry Research Laboratory, SLT Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur- 495 009, (CG). India.
authors.forename: Avineesh
authors.initials: A
authors.lastname: Singh
authors.affiliation: Medicinal Chemistry Research Laboratory, SLT Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur- 495 009, (CG). India.
authors.forename: Preeti
authors.initials: P
authors.lastname: Patel
authors.affiliation: Medicinal Chemistry Research Laboratory, SLT Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur- 495 009, (CG). India.
authors.forename: Vijay K
authors.initials: VK
authors.lastname: Patel
authors.affiliation: Medicinal Chemistry Research Laboratory, SLT Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur- 495 009, (CG). India.
authors.forename: Deepak K
authors.initials: DK
authors.lastname: Jain
authors.affiliation: Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman. Malaysia.
authors.forename: Ravichandran
authors.initials: R
authors.lastname: Veerasamy
authors.affiliation: Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra-136 119, (Haryana). India.
authors.forename: Prabodh C
authors.initials: PC
authors.lastname: Sharma
authors.affiliation: Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur. India.
authors.forename: Harish
authors.initials: H
authors.lastname: Rajak
mesh_terms: D000818:Animals; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006655:Histone Deacetylases / Q000378:metabolism; D006657:Histones / Q000378:metabolism; D006801:Humans; D051379:Mice; D008819:Mice, Nude
chemical_list: D056572:Histone Deacetylase Inhibitors; D006657:Histones; D006655:Histone Deacetylases
keywords: Colorectal cancer; HDAC inhibitors; fluoropyrimidines; kinase inhibitors; proteasome inhibitors; topoisomerase
  inhibitors